Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data presented by Eli Lilly—they have gone up against one another.